Bristol Myers Pushes Data Readout For Key Alzheimer's Psychosis Study After Irregularities - Bristol-Myers Squibb (NYSE:BMY)

Bristol Myers Pushes Data Readout For Key Alzheimer's Psychosis Study After Irregularities - Bristol-Myers Squibb (NYSE:BMY)

Bristol Myers Squibb & Co. (NYSE:BMY) on Wednesday said it would enroll additional patients in the ADEPT-2 Phase 3 study. BMY shares are climbing with conviction. See the market dynamics here. The ADEPT-2 study is a multicenter, randomized, double-blind, placebo-controlled trial assessing the safety and efficacy of Cobenfy in subjects with psychosis associated with Alzheimer’s disease dementia. The study is designed to evaluate the primary endp…

Bristol to enroll more patients in key study of Cobenfy in Alzheimer’s psychosis

The company is hoping to expand its drug Cobenfy into additional neuropsychiatric indications beyond schizophrenia.

After finding ‘irregularities,’ Bristol Myers to extend key trial of Cobenfy in Alzheimer’s psychosis

Data from the "ADEPT-2" study, which analysts had hoped would arrive before year's end, are now expected sometime in 2026.

Bristol Myers Squibb Announces Continuation of ADEPT-2 Phase 3 Study in Psychosis Associated with Alzheimer's Disease

PRINCETON, N.J.--(BUSINESS WIRE)--Dec 3, 2025-

Delay on Cobenfy Alzheimer Disease Psychosis Data Following Phase 3 Study “Irregularities,” New Patients Enrolled

Bristol Myers Squibb expands patient enrollment in the ADEPT-2 study, exploring Cobenfy's potential for treating Alzheimer disease-related psychosis.

Updated: Bristol Myers pushes back Cobenfy readout after trial site 'irregularities'

Bristol Myers Squibb’s hotly anticipated Cobenfy readout in Alzheimer’s-associated psychosis will have to wait. Because of “irregularities” at a “small number” of trial sites, the pharma company said Wednesday that some patient data had to ...